Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI

OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics to help fight infectious diseases. Shares of the diagnostic company are skyrocketing 206% through early trading on Tuesday, December 13, 2022. Over the past three months, OpGen has seen average daily volume of 408,550 shares. However, volume of 145.83 million shares or dollar volume of around $57.49 million, has already exchanged hands through early trading.

Shares of OpGen are soaring after the company reported positive top line data from its clinical trial of the Unyvero UTI panel to determine diagnostic ability to detect urinary tract infections. The study enrolled over 1,800 patient samples across four U.S.-based clinical trial sites.

OpGen developed the Unyvero UTI panel to help test for a broad range of bacterial and fungal pathogens from urine specimens. The test specifically focuses on quantitative detection of microorganisms.

The primary endpoint was met for Unyvero UTI with an overall weighted average sensitivity reading of 96.4% and an overall weighted average specificity of 97.4% compared to each test site’s standard of care microbiology tests. The results are in line with OpGen’s initial interim results from the first half of the trial.

Using a total of 1,858 prospective and archived samples, the clinical trial utilized over 3,300 Unyvero cartridges in controlled and reproducible lab tests across different trial sites. Based on the strong data from the clinical trial, OpGen says it plans to begin preparing a De Novo request package for submission to the U.S. FDA.

“Having completed the study as planned, we have successfully generated a large and very comprehensive study data set with multiple reference methods. We’d like to thank our study sites for their contributions in generating these data.”, said Johannes Bacher, Chief Operating Officer of OpGen. “Now that we have unblinded the results, we are excited to proceed with our in-depth analysis and compile the data submission to the FDA over the next few months.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.